Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
|
|
Fortress Biotech, Inc. (FBIO) > Segments
|
|
| Pharmaceutical and Biotechnology Product Development |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | 10-K |
| Revenues | 2.1 | 5.7 | 1.1 | 1.7 | 3.5 | 1.7 | 2.6 | 0.6 |
| Revenue growth | -63.3% | 429.7% | -37.5% | -51.3% | 103.2% | -32.9% | 335.6% | |
| Research and development | 123.9 | 112.3 | 64.1 | 81.3 | 87.4 | 52.5 | 35.1 | 29.8 |
| General and administrative | | | | 35.9 | 40.0 | 39.3 | 26.8 | 17.1 |
| EBIT | | | | | -134.6 | -97.8 | -59.3 | -46.3 |
| EBIT margin | | | | | -3840.1% | -5671.0% | -2308.1% | -7842.7% |
| |
| Total assets | 189.1 | 299.2 | 283.4 | 199.1 | 130.6 | 161.2 | 115.1 | 116.5 |
| ROA | 0.0% | 0.0% | 0.0% | 0.0% | -103.1% | -61.6% | -51.5% | -39.7% |
| |
| Revenue Mix | 2.7% | 8.2% | 2.3% | 4.7% | 13.0% | 11.1% | 15.6% | 68.4% |
|